Rivastigmine Patch
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Mild to Moderate Alzheimer's Disease
Conditions
Mild to Moderate Alzheimer's Disease
Trial Timeline
May 9, 2016 → May 7, 2018
NCT ID
NCT02703636About Rivastigmine Patch
Rivastigmine Patch is a approved stage product being developed by Novartis for Mild to Moderate Alzheimer's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02703636. Target conditions include Mild to Moderate Alzheimer's Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02703636 | Approved | Completed |
| NCT01380288 | Pre-clinical | Completed |
| NCT00835159 | Approved | Completed |
Competing Products
20 competing products in Mild to Moderate Alzheimer's Disease